C4 Imaging is a technology company focused on developing innovative medical devices that enable clinicians to more accurately perform image-guided procedures. C4 Imaging's patent portfolio is centered on its proprietary positive-signal MRI contrast agent (C4) and encapsulation technology.
C4 Imaging recently launched its first product, the Sirius™ MRI Marker. Sirius™ is the first commercially available positive-signal MRI Marker and is a permanently implantable medical device used in the management of prostate cancer. In prostate brachytherapy, Sirius™ MRI Markers are attached to radioactive seeds and inserted into the prostate. Physicians can view and evaluate seed placement utilizing MRI, allowing for an accurate assessment of treatment quality.
C4 Imaging is now developing multi-modality (MRI and CT) products that address significant opportunities outside of prostate cancer; with breast cancer management and improved radiotherapy delivery being the next target markets. In addition, C4 Imaging is assessing the opportunity for C4 to be developed as an alternative to gadolinium based MRI contrast agents.
For further information please contact:
President and CEO
Tel: 609 933 5895
Copyright © 2016.
Sirius is a trademark of C4 Imaging.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/c4-imaging-to-present-at-the-medtech-showcase-2017-300383135.html
SOURCE C4 Imaging